Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has provided an update.
ASKA Pharmaceutical Holdings Co., Ltd. announced corrections to its financial results for the first quarter of FY2025, specifically regarding sales transactions by its Vietnamese subsidiary, Hataphar. The company revised its sales recording method from a gross to a net basis, resulting in adjustments to net sales and cost of sales by 1,680 million yen each, but with no impact on profits. This correction reflects a more accurate representation of the company’s financial dealings and ensures compliance with accounting policies, potentially affecting stakeholders’ perception of the company’s financial transparency.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2305.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of medical products. The company is listed on the Tokyo Stock Exchange and is involved in various pharmaceutical activities, including the production and sale of drugs and health-related products.
Average Trading Volume: 75,832
Technical Sentiment Signal: Sell
Current Market Cap: Yen55.73B
Learn more about 4886 stock on TipRanks’ Stock Analysis page.